 CAMBRIDGE, Mass.--BUSINESS WIRE--Syros Pharmaceuticals NASDAQ:SYRS, a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research AACR Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana. The online-only e-poster will include data that show Syros orally available, selective CDK12 inhibitor has potent single agent acti 